Affordable Access

deepdyve-link
Publisher Website

Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial.

Authors
  • Cezard, J-P1
  • Munck, A
  • Mouterde, O
  • Morali, A
  • Lenaerts, C
  • Lachaux, A
  • Turck, D
  • Schmitz, J
  • Maurage, C
  • Girardet, J-P
  • Belli, D
  • Lamireau, T
  • Sarles, J
  • Chouraqui, J-P
  • Descos, B
  • Dabadi, A
  • Meyer, M
  • Olives, J-P
  • Mary, J-Y
  • 1 Service de gastroentérologie pédiatrique, mucoviscidose, nutrition pédiatrique, centre de référence des maladies digestives rares de l'enfant, hôpital Robert-Debré, 75019 Paris cedex 19, France. [email protected] , (France)
Type
Published Article
Journal
Gastroentérologie Clinique et Biologique
Publisher
Elsevier
Publication Date
January 2009
Volume
33
Issue
1 Pt 1
Pages
31–40
Identifiers
DOI: 10.1016/j.gcb.2008.07.007
PMID: 19118966
Source
Medline
License
Unknown

Abstract

Overall, mesalazine does not appear to be an effective maintenance treatment in pediatric CD.

Report this publication

Statistics

Seen <100 times